MUSK and myasthenia gravis: In a subsequent phase II trial, 43 patients with AChR or MuSK positive generalised MG were randomized to 3 weekly subcutaneous infusions of placebo or rozanolixizumab, and then 4 weeks later, were re-randomized to 3 weekly doses of either 4 or 7 mg/kg.